Global Protein Therapeutics Market 2017-2021

December 30, 2016
SKU:
IRTNTR11316
This industry research report identifies AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck, and Novo Nordisk as the key vendors in the global protein therapeutics market. This industry research report presents a competitive analysis of the market by product type, by therapy area, and by protein function. The report also presents as detailed analysis of the market based on geographical regions such as the Americas, APAC, and EMEA.

Overview of the global protein therapeutics market

Market research analysts at Technavio predict that the global protein therapeutics market will grow steadily during the next four years and post a CAGR of almost 8% by 2021. This market research analysis identifies the increased demand for monoclonal antibodies (mAbs) as one of the primary growth factors for this market. mAbs accounts for a major share of protein therapeutics. The increasing usage of mAbs in various therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy will drive the growth of the market. Additionally, mAbs are also used in the formulation of biopharmaceutical drugs for the treatment of different diseases including cancer and ulcerative colitis which will also aid in the market’s growth in the coming years.

This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the market throughout the forecast period. Factors such as the increase in uptake of the existing protein therapeutics and the rise in approvals for certain formulations that will induce more vendors to conduct R&D activities and enter the market, will boost the market’s growth prospects in this region.  

Competitive landscape and key vendors

The market is highly competitive and consists of numerous small and large-scale vendors who operate at a local or global scale. To enhance their global reach and increase revenue shares, vendors have started forming strategic alliances to manufacture and market drugs. Companies engaged in manufacturing and marketing protein therapeutics that can effectively treat various disorders will gain a competitive edge over the other vendors in the market. The market’s growth opportunities will induce new vendors to enter the market, which will intensify the level of competition in the already competitive market.

The leading vendors in the market are -

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

The other prominent vendors in the market are Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Segmentation by product type and analysis of the protein therapeutics market

  • mAbs
  • Insulin
  • Clotting factors
  • Erythropoietin
  • Human growth hormone

During 2016, the monoclonal antibodies (mAbs) segment accounted for the major shares and dominated this market. The change in lifestyle and the sedentary work life that lead to the rise in incidences of cancer and the benefits of next-generation antibodies, will boost the growth of the protein therapeutics market in this segment during the predicted period. 

Segmentation by therapy area and analysis of the protein therapeutics market

  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

Metabolic and endocrine disorders including diabetes mellitus, growth hormone deficiency, chronic renal insufficiency, and Turner syndrome, affect the body's ability to produce nutrients and vitamins and also result in the production of insufficient or excess hormones. Aldurazyme, Naglazyme, Fabrazyme, Zymase, Sandostatin, and Streptase are some protein therapeutics used to treat metabolic and endocrine disorders.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global protein therapeutics market?
  • What are the key market trends impacting the growth of the global protein therapeutics market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global protein therapeutics market?
  • What are the market opportunities and threats faced by the vendors in the global protein therapeutics market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global protein therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports